Neolpharma
One of 10,000+ projects Taiyo tracks in Mexico.
Source: IFC Project Disclosures
Grupo Neolpharma (the “Company”) is a Mexico-based, family-owned, pharmaceutical company focused on the development, manufacture, distribution and sale of branded and unbranded generic medicines. Neolpharma has presence in Mexico, Puerto Rico, Peru and Ecuador. It exports from Mexico to Colombia, El Salvador, Panama, Costa Rica, Guatemala, Honduras and the Dominican Republic.Neolpharma owns an act
- Status
- Prospective
- Sector
- Manufacturing (Industrial)
- Location
- Mexico
- Updated
- 19 Nov 2026
- Source
- IFC Project Disclosures
ConstructChat
Ask ConstructChat about Neolpharma
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | active |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Grupo Neolpharma (the “Company”) is a Mexico-based, family-owned, pharmaceutical company focused on the development, manufacture, distribution and sale of branded and unbranded generic medicines. Neolpharma has presence in Mexico, Puerto Rico, Peru and Ecuador. It exports from Mexico to Colombia, El Salvador, Panama, Costa Rica, Guatemala, Honduras and the Dominican Republic.Neolpharma owns an active pharmaceutical ingredient (“API”) production plant “NeolSym”, five pharmaceutical finished formulations production plants (i.e., Psicofarma Tlalpan, Psicofarma DN, Neolpharma Vallejo, and Alpharma in Mexico City’s metropolitan area, and Psicofarma in Toluca, state of Mexico); and one US-FDA/EMA approved plant in Puerto Rico (Neolpharma PR); two distribution companies; and a pharmacy chain in Mexico with 47 branches. The plant in Toluca (Psicofarma Toluca) was recently acquired and it is starting operations in 2019. Neolpharma is one of the leading domestic pharmaceutical companies in Mexico, primarily focused on prescription generics, with a portfolio of over 250 products (1,100 SKU’s) in therapeutic areas such as central nervous system, cardiovascular, oncology and diabetes. The proposed IFC’s financing aims to support Grupo Neolpharma’s expansion plan which includes the construction and equipment of a new injectables facility in Mexico City (Psicofarma DN), expansion of the existing API production plant (NeolSym) in Ecatepec, Mexico, climate related projects (clean energy utilizing new cogeneration units on three of the production plants) and other expenditures associated with Neolpharma’s expansion plan (the “Project”). The total Project Cost is estimated at approximately US$100 million. The proposed IFC investment is an up to US$15 million corporate A Loan for IFC’s own account plus mobilization through Canada-IFC Blended Climate Finance Program for up to US$15 million for assets in Mexico. |
Original sector | other |
Location
Country | Mexico |
Source
Source | IFC Project Disclosures |
URL |
More Details
Record type | Project |
Sector | Manufacturing (Industrial) |
Article published date | 2026-09-09 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Manufacturing (Industrial) projects in Mexico
- El Cortijo Wind Farm Tamaulipas
- Norte III Combined Cycle Power Plant Chihuahua
- Samalayuca II CCGT Plant Chihuahua Mexico
- Macquarie Marena Wind Farm
- Veracruz and Medellin Water and Sewerage Services
- Viaducto Bicentenario (Phase 1)
- Tuxpan Container Terminal
- Rio de los Remedios-Ecatepec urban toll road (Phase I)
